Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et forsøg for at vurdere Cobicistat boostet Venetoclax i kombination med azacitidin hos voksne patienter med nyligt diagnosticeret AML (HO171)

Et enkeltarms fase II-forsøg til vurdering af Cobicistat boostet Venetoclax i kombination med azacitidin (sc) hos voksne patienter med nyligt diagnosticeret akut myeloid leukæmi (AML), som ikke anses for at være kandidater til intensive behandlingsregimer

The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

142

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Gerwin Huls, prof
  • Telefonnummer: +3150 361 2354
  • E-mail: g.huls@umcg.nl

Studiesteder

      • 's-Hertogenbosch, Holland
        • Rekruttering
        • NL-Den Bosch-JBZ
        • Kontakt:
          • A.H.E. Herbers, Dr.
      • Amersfoort, Holland
        • Rekruttering
        • NL-Amersfoort-MEANDERMC
        • Kontakt:
          • M.F. Corsten, Dr.
      • Amsterdam, Holland
        • Rekruttering
        • NL-Amsterdam-OLVG
        • Kontakt:
          • H. Mooij, Dr.
      • Amsterdam, Holland
        • Rekruttering
        • NL-Amsterdam-AUMC
        • Kontakt:
          • C. Alhan, Dr.
      • Arnhem, Holland
        • Rekruttering
        • NL-Arnhem-RIJNSTATE
        • Kontakt:
          • M.L.H. Cuijpers, Dr.
      • Breda, Holland
        • Rekruttering
        • NL-Breda-AMPHIA
        • Kontakt:
          • R.B. Fiets, Dr.
      • Dordrecht, Holland
        • Rekruttering
        • NL-Dordrecht-ASZ
        • Kontakt:
          • P.E. Westerweel, Dr.
      • Eindhoven, Holland
        • Rekruttering
        • NL-Eindhoven-MAXIMAMC
        • Kontakt:
          • L.W. Tick, Dr.
      • Eindhoven, Holland
        • Rekruttering
        • NL-Eindhoven-CATHARINA
        • Kontakt:
          • M.J. Cruijsen, Dr.
      • Enschede, Holland
        • Rekruttering
        • NL-Enschede-MST
        • Kontakt:
          • T.J.F. Snijders, Dr.
      • Groningen, Holland
        • Rekruttering
        • NL-Groningen-UMCG
        • Kontakt:
          • G.A. Huls, Prof. dr.
      • Leeuwarden, Holland
        • Rekruttering
        • NL-Leeuwarden-MCL
        • Kontakt:
          • B. Franken, Dr.
      • Leiden, Holland
        • Rekruttering
        • NL-Leiden-LUMC
        • Kontakt:
          • P.A. von dem Borne, Dr.
      • Maastricht, Holland
        • Rekruttering
        • NL-Maastricht-MUMC
        • Kontakt:
          • C.H.M.J. van Elssen, Dr.
      • Nieuwegein, Holland
        • Rekruttering
        • NL-Nieuwegein-ANTONIUS
        • Kontakt:
          • O. de Weerdt, Dr.
      • Nijmegen, Holland
        • Rekruttering
        • NL-Nijmegen-RADBOUDUMC
        • Kontakt:
          • N.A. de Jonge, Dr.
      • Nijmegen, Holland
        • Rekruttering
        • NL-Nijmegen-CWZ
        • Kontakt:
          • S. de Jonge, Dr.
      • The Hague, Holland
        • Rekruttering
        • NL-Den Haag-HAGA
        • Kontakt:
          • D. van Lammeren, Dr.
      • Zwolle, Holland
        • Rekruttering
        • NL-Zwolle-ISALA
        • Kontakt:
          • T.T. de Waal, Dr.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

  • Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.

  • Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.

  • WHO performance status 0, 1 or 2 (appendix E).

  • Leukocytes < 30 x109/L

  • Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:

    • Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
    • Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
    • Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
  • Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.

  • Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.

  • Written informed consent.

  • Patient is capable of giving informed consent.

  • Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.

Exclusion Criteria:

A patient who meets any of the following criteria cannot be included in this study:

  • Acute promyelocytic leukemia.

  • Myelodysplastic syndrome (MDS).

  • Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).

  • Diagnosis of any previous or concomitant malignancy is an exclusion criterion:

    • except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
    • except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
  • Blast crisis of chronic myeloid leukemia.

  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).

  • Cardiac dysfunction as defined by:

    • Myocardial infarction within the last 3 months of study entry, or
    • Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
    • Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
    • Unstable cardiac arrhythmias.
  • History of stroke or intracranial haemorrhage within 6 months prior to registration.

  • Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).

  • History of non-compliance to medical regimens or considered unreliable with respect to compliance.

  • Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.

  • Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.

  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

  • Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.

  • Intolerability, contra-indication or allergy to one of the study drugs.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: single arm arm extension phase

prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1

during run-in and extention phase: from Cycle 1 until relapse

during run-in and extention phase: from Cycle 1 until relapse

during run-in phase: from cycle 2 until relapse

during extension phase: from cycle 1 until relapse

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
Tidsramme: 6-8 months

run-in phase

6-8 months
Overall survival (OS).
Tidsramme: 48 months

extension phase

48 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
Tidsramme: 6-8 months

run-in phase

6-8 months
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months

extension phase

48 months
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months

extension phase

48 months
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months

extension phase

48 months
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsramme: 48 months

extension phase

48 months
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsramme: 48 months

extension phase

48 months
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
Tidsramme: 48 months

extension phase

48 months
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
Tidsramme: 48 months

extension phase

48 months
Event free survival (EFS).
Tidsramme: 48 months

extension phase

48 months
Relapse-free survival (RFS).
Tidsramme: 48 months

extension phase

48 months
Incidence and severity of adverse events according to CTCAE version 5.0.
Tidsramme: 48 months

extension phase

48 months
Early (30-day and 60-day) mortality (in general, non-leukemic).
Tidsramme: 48 months

extension phase

48 months
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
Tidsramme: 48 months

extension phase

48 months
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
Tidsramme: 48 months

extension phase

48 months
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
Tidsramme: 48 months

extension phase

48 months
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
Tidsramme: 48 months

extension phase

48 months
Clonal evolution during treatment.
Tidsramme: 48 months

extension phase

48 months
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
Tidsramme: 48 months

extension phase

48 months
Cost-savings on venetoclax drug costs.
Tidsramme: 48 months

extension phase

48 months
Adherence to venetoclax and cobicistat.
Tidsramme: 48 months

extension phase

48 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. januar 2024

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

4. juli 2023

Først indsendt, der opfyldte QC-kriterier

23. august 2023

Først opslået (Faktiske)

28. august 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

23. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner